PPARγ and the treatment of insulin resistance

Trends in Endocrinology and Metabolism

Volumn 11, Issue 9, 2000, Pages 362-368

  Olefsky, Jerrold M ^a   Saltiel, Alan R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TROGLITAZONE; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; DRUG MECHANISM; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMAL; HUMAN; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0033779728     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(00)00306-4     Document Type: Review

References (50)

1. Insulin resistance
2. Role of insulin resistance in human disease
3. Deconstructing type 2 diabetes
4. Slow glucose removal rate and hyperinsulinemia precede the development of type 2 diabetes in the offspring of diabetic parents
5. Effects of troglitazone on plasminogen activator inhibitor-1 (PAI-1) concentration in blood in patients with type 2 diabetes mellitus and lean and obese normal subjects
6. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes
7. Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice
8. Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats
9. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat
10. TNF-α-induced insulin resistance in vivo and its prevention by troglitazone
11. Troglitazone prevents hyperglycemia-induced but not glucosamin-induced insulin resistance
12. A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats
13. Metabolic effects of a new oral hypoglycemic agent, CS-045, in non-insulin dependent diabetic subjects
14. Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM
15. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes
16. Metabolic effects of troglitazone in type 1 diabetes mellitus: A randomized, double-blind placebo-controlled trial
17. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
18. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
19. Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM
20. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone study group
21. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells
22. An antidiabetic thiazlidinedione is a high affinity ligand for PPARγ
23. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
24. Structural organization of mouse peroxisome proliferator-activated receptor γ gene: Alternative promoter use and different splicing yield two PPARγ isoforms
25. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPARα, -β and -γ in the adult rat
26. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
27. 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
28. The coregulator exchange in transcriptional functions of nuclear receptors
29. A novel, multifunctional c-Cbl binding protein in insulin receptor signaling in 3T3-L1 adipocytes
30. CAP defines a second signaling pathway required for insulin-stimulated glucose transport
31. Thiazolidinediones and insulin resistance: PPARγ-activation stimulates expression of the CAP gene
32. Cloning and characterization of a functional PPARγ-responsive element in the promoter of the CAP gene
33. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
34. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARγ2 and RXRα
35. Skeletal muscle peroxisome proliferator-activated receptor γ expression in obesity and non-insulin dependent diabetes mellitus
36. Peroxisome proliferator-activated receptor gene expression in human tissues: Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
37. In vitro studies on the action of CS-045. A new antidiabetic agent
38. Troglitazone action is independent of adipose tissue
39. PPARγ is required for placental, cardiac and adipose tissue development
40. Improved insulin-sensitivity in mice heterozygous for PPARγ, deficiency
41. PPARγ, mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
42. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
43. Pro12Ala missense mutation of the peroxisome proliferator activated receptor γ and diabetes mellitus
44. Effect of the Pro 12Ala variant of the human peroxisome proliferator-activated receptor γ2 gene on adiposity, fat distribution and insulin sensitivity in Japanese men
45. Dominant negative mutations in human PPARγ, associated with severe insulin resistance, diabetes and hypertension
46. Nuclear receptor repression mediated by a complex containing SMRT, mSIN3AZ, and histone deacetylase
47. Differential activation of peroxisome proliferator-activated receptor γ by troglitazone and rosiglitazone
48. The language of covalent histone modifications
49. The molecular pharmacology of SERMs
50. Regulation of gene expression in vivo by PPARγ